Comparative Pharmacology
Head-to-head clinical analysis: DOLENE versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE versus TALWIN.
DOLENE vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic